Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017

This study included 20 dogs with a new diagnosis of leishmaniosis under allopurinol treatment (10 mg/kg/12 h during 12 months). Dogs were evaluated at time of diagnosis, one, six and twelve months after diagnosis and treatment with allopurinol, additionally 11/20 dogs were also evaluated at 3 months. Each clinical evaluation included the following tests (physical exam, abdominal ultrasound, UPC ratio, urinalysis, hematology, biochemical panel and Leishmania serology). All dogs had an unremarkable urinary ultrasound without urinary sediment before treatment. At onemonth control, 4/20 dogs had xanthinuria, 2/20 mineralization of pelvic recesses (MPR) and 1/20 vesical urolithiasi. At three-month control, 4/11 had xanthinuria, 4/11 bilateral MPR and 2/11 urolithiasis (located in renal pelvis and bladder in 1 dog and the other in bladder). At 6-month control, 4/20 dogs had xanthinuria, 6/20 bilateral MPR, and 4/20 urolithiasis (located in renal pelvis and bladder in 2 dogs and in renal pelvis in the other two). At 12months control, 7/20 dogs had xanthinuria, 7/20 bilateral MPR, and 6/20 urolithiasis (located in bladder in 3 dogs and in renal pelvis in the other 3). Dogs that suffered from xanthinuria and renal mineralization or urolithiasis were treated with low purine diet. Reduction of xanthinuria and uroliths size was observed in 3 dogs with compliant owners and strict diet treatment but MPR persisted.